HEALTHSTAT NEWS
Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story
A randomized trial of Grail’s Galleri multi-cancer early detection test, conducted with the U.K. National Health Service, showed no reduction in stage 3 and 4 cancers as its primary endpoint. An oncologist highlights additional context despite the negative trial results.
Mentioned
Related Signal
Adjacent reporting
- Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
- Landmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future treatments
- Ecotypes of triple-negative breast cancer in response to chemotherapy
- GSK reports promising early results in ovarian and womb cancer drug trial
- Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug
- New pancreatic cancer pill could reshape treatment as early trial results stun researchers